Good science behind hepatitis C virus antiviral drug development: Necessary but not sufficient

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|46|5|1317-1318

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.46, Iss.5, 2007-11, pp. : 1317-1318

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging Antiviral Drugs for Hepatitis C Virus

By  

Reviews on Recent Clinical Trials, Vol. 4, Iss. 3, 2009-09 ,pp. : 179-184

Bentham Science Publishers

Access to resources Recommend Favorite

The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 44, Iss. 8, 2016-10 ,pp. : 856-865

John Wiley & Sons Inc

Access to resources Recommend Favorite

Direct‐acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1298-1303

John Wiley & Sons Inc

Access to resources Recommend Favorite

Direct‐acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1298-1303

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection

By  

Journal of Innate Immunity, Vol. 7, Iss. 5, 2015-03 ,pp. : 530-544

Karger

Access to resources Recommend Favorite